Targeting S100A4 by employing chemotherapeutic drugs such as MET, antibodies, or small-molecule inhibitors might provide a new potential therapy for systemic sclerosi, amyotrophic lateral sclerosis and cancers. Here, MET is linked to systemic sclerosis.